Table 1.

Comparative analysis of antiproliferative IC₅₀ values for Compounds 21–30 and Erlotinib across different cancer cell lines.

Comp.	Cell Viability %	Antiproliferative Activity IC50 ± SEM (nM)
		A-549	MCF-7	Panc-1	HT-29	Average IC50 (GI50)
21	90	26 ± 2	30 ± 3	28 ± 2	28 ± 2	28
22	89	32 ± 3	35 ± 3	34 ± 3	32 ± 3	33
23	91	29 ± 2	34 ± 3	32± 3	32 ± 3	32
24	90	27 ± 2	31 ± 3	29± 2	28 ± 2	29
25	88	40 ± 3	45 ± 4	42 ± 4	42 ± 4	42
26	92	35 ± 3	40 ± 4	36 ± 3	36 ± 3	37
27	88	36 ± 3	42 ± 4	38 ± 3	38 ± 3	38
28	89	25 ± 2	30 ± 3	26 ± 2	26 ± 2	27
29	91	27 ± 2	31 ± 3	30 ± 3	30 ± 3	30
30	90	23 ± 2	28 ± 2	24 ± 2	24 ± 2	25
Erlotinib	ND	30 ± 3	40 ± 3	30 ± 3	30 ± 3	33

ND: Not Determined.